Home > Insider Trading > Filing (0001062993-22-016555)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1621443	Zynerba Pharmaceuticals Inc.	ZYNE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1219866	Armando Anido	C/O Zynerba Pharmaceuticals, Inc. 80 W. Lancaster Avenue, Suite 300 Devon PA 19333	Chairman & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-07-18	43,164	$0.00	623,587	No	4	A	Direct
Common Stock	Disposition	2022-07-19	11,899	$1.10	611,688	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	26,595	Indirect	See footnote
Common Stock	13,297	Indirect	See footnote

Footnotes

On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 43,164 performance-based restricted stock awards granted in a prior year.
This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.